Modus Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Modus Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$3K	–	264
2021 Q2	$3K	Buy	+500	New	+$2.93K	﹤0.01%	243

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Modus Advisors's CLVS Position: Q3 2021 in Review

Modus Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 500 shares — an estimated $3K sold.

Modus Advisors first reported a position in CLVS in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

Modus Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
Modus Advisors sold 500 Clovis Oncology, Inc. shares in Q3 2021, an estimated $3K.
Modus Advisors first reported a position in Clovis Oncology, Inc. in Q2 2021 and held it in 1 quarter.
Modus Advisors's Clovis Oncology, Inc. position peaked at $3K in Q2 2021.
157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Modus Advisors's 13F filing for Q3 2021, filed 8 Oct 2021.